ヒトメタニューモウイルス（hMPV）治療薬の世界市場レポート 2025年

ヒトメタニューモウイルス（hMPV）治療薬市場規模は、今後数年間で力強い成長が見込まれます。2029年には6.2％の複合年間成長率（CAGR）で9億米ドルに成長します。予測期間中に予測される成長は、支持療法に対する需要の高まり、政府やNGOの資金提供の増加、呼吸器感染症に対する意識の高まり、小児呼吸器疾患患者の増加、標的治療に対する需要の高まりなどに起因すると考えられます。この期間の主な動向としては、診断プラットフォームへの技術統合、抗ウイルス薬開発の進展、ワクチン研究とデリバリーシステムの進歩、技術主導のポイントオブケア検査、分子診断の改善などが挙げられます。

呼吸器感染症の有病率の増加は、今後のヒトメタニューモウイルス（hMPV）治療薬市場の拡大を大きく牽引すると予想されます。呼吸器感染症は、鼻、喉、気道、肺を含む呼吸器に影響を及ぼします。こうした感染症の増加は、大気汚染レベルの上昇に大きく起因しています。hMPV治療薬は、抗ウイルス治療や支持療法を通じてウイルスの複製や炎症を抑えることで、hMPVによる呼吸器感染症の治療に重要な役割を果たしています。これにより、特に乳幼児、高齢者、免疫不全患者などの脆弱な集団の健康状態が改善されます。例えば、2024年6月、政府機関であるオーストラリア保健福祉研究所は、2023年に慢性閉塞性肺疾患（COPD）がオーストラリア全体の疾病負担の3.6％を占めると報告しました。COPDは呼吸器疾患全体の50％を占め、2022年には63万8,000人（人口の2.5％）がCOPD患者であると推定されています。したがって、呼吸器感染症の有病率の増加がヒトメタニューモウイルス（hMPV）治療薬市場の成長を促進しています。

ヒトメタニューモウイルス（hMPV）治療薬市場の主要企業は、hMPV感染を効果的に治療するために、モノクローナル抗体などの標的抗ウイルス療法の開発に注力しています。モノクローナル抗体（mAbs）は、病気と闘う免疫系の自然な能力を複製する実験室で生産されるタンパク質です。これらの抗体は、有害な抗原や細胞に特異的に結合し中和することで、がんや自己免疫疾患など、さまざまな疾患に対する標的療法を提供します。例えば、2024年10月、英国を拠点とするバイオ医薬品会社Vicebio Ltd.は、TCGXが主導し、ゴールドマン・サックス・オルタナティブやその他の投資家の支援を得て、シリーズB資金調達で1億米ドルを確保しました。この資金調達により、RSVとhMPVを標的とする二価ワクチンVXB-241の第1相臨床試験が進められ、2025年半ばまでに予備的な結果が出る見込みです。また、今回の資金調達により、RSV、hMPV、パラインフルエンザウイルス3を標的とする3価ワクチンであるVXB-251の開発が加速され、高齢者集団における重大な医療課題の解決を目指します。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- 金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界ヒトメタニューモウイルス（hMPV）治療薬PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場：成長率分析
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場の実績：規模と成長, 2019-2024
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場の予測：規模と成長, 2024-2029, 2034F
• 世界ヒトメタニューモウイルス（hMPV）治療薬総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のヒトメタニューモウイルス（hMPV）治療薬市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 解熱剤
• 鼻づまり解消薬
• 咳止め薬
• その他の薬物クラス
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場：最終用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院と診療所
• 診断および参照検査室
• 学術調査機関
• その他の用途
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場解熱剤の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 非ステロイド性抗炎症薬（NSAID）
• アセトアミノフェン（パラセタモール）
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場充血除去薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 鼻づまり解消薬
• 経口充血除去薬
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場咳止め薬の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• デキストロメトルファン
• コデイン
• ベンゾナテート
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場、その他の薬物クラスのタイプ別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 抗ウイルス剤
• 抗生物質
• 吸入コルチコステロイド

第7章 地域別・国別分析

• 世界のヒトメタニューモウイルス（hMPV）治療薬市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のヒトメタニューモウイルス（hMPV）治療薬市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• ヒトメタニューモウイルス（hMPV）治療薬市場：競合情勢
• ヒトメタニューモウイルス（hMPV）治療薬市場：企業プロファイル
  • Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • Moderna Inc Overview, Products and Services, Strategy and Financial Analysis
  • Riverside Health System Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Narayana Health
• Vir Biotechnology Inc.
• Fortis Healthcare
• Apollo Diagnostics
• Pathkind Diagnostics Pvt Ltd
• Max Healthcare
• LalPathLabs
• Bio Farma
• Metropolis Healthcare
• American Lung Association
• Enanta Pharmaceuticals Inc.
• Regency Healthcare
• The Native Antigen Company
• Max Lab
• Agilus Diagnostics

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• ヒトメタニューモウイルス（hMPV）治療薬市場2029：新たな機会を提供する国
• ヒトメタニューモウイルス（hMPV）治療薬市場2029：新たな機会を提供するセグメント
• ヒトメタニューモウイルス（hMPV）治療薬市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Human metapneumovirus (hMPV) therapeutics refers to medical treatments aimed at managing and alleviating the symptoms caused by hMPV, a respiratory virus that typically affects infants, older adults, and immunocompromised individuals. These therapeutics work by inhibiting viral replication, blocking the virus from entering host cells, and modulating the immune response to reduce inflammation and the severity of the disease.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The primary drug classes for hMPV therapeutics include antipyretics, decongestants, cough suppressants, and other related medications. An antipyretic is a substance that helps reduce fever by lowering the body's temperature, acting on the hypothalamus. These drugs are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies. They are utilized in various end-use settings such as hospitals, clinics, diagnostic and reference laboratories, academic and research institutions, and other healthcare facilities.

The human metapneumovirus (hMPV) therapeutics market research report is one of a series of new reports from The Business Research Company that provides human metapneumovirus (hMPV) therapeutics market statistics, including the human metapneumovirus (hMPV) therapeutics industry global market size, regional shares, competitors with the human metapneumovirus (hMPV) therapeutics market share, detailed human metapneumovirus (hMPV) therapeutics market segments, market trends, and opportunities, and any further data you may need to thrive in the human metapneumovirus (hMPV) therapeutics industry. This human metapneumovirus (hMPV) therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The human metapneumovirus (hMPV) therapeutics market size has grown strongly in recent years. It will grow from $0.66 billion in 2024 to $0.70 billion in 2025 at a compound annual growth rate (CAGR) of 6.6%. The growth observed during the historic period can be attributed to increased awareness of viral respiratory infections, a rising incidence of pediatric respiratory illnesses, higher hospitalization rates, expanded global health surveillance efforts, and a growing research focus on emerging respiratory viruses.

The human metapneumovirus (hMPV) therapeutics market size is expected to see strong growth in the next few years. It will grow to $0.90 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth projected during the forecast period can be attributed to the rising demand for supportive care treatments, increased government and NGO funding, growing awareness of respiratory infections, a rise in pediatric respiratory illness cases, and a higher demand for targeted therapies. Key trends during this period include the integration of technology in diagnostic platforms, advancements in antiviral drug development, progress in vaccine research and delivery systems, technology-driven point-of-care testing, and improvements in molecular diagnostics.

The growing prevalence of respiratory infections is expected to significantly drive the expansion of the human metapneumovirus (hMPV) therapeutics market in the future. Respiratory infections affect the respiratory tract, which includes the nose, throat, airways, and lungs. The increasing number of these infections is largely attributed to rising levels of air pollution. Pollutants such as particulate matter and nitrogen dioxide can irritate and weaken the respiratory tract, making individuals more vulnerable to infections. hMPV therapeutics play a crucial role in treating respiratory infections caused by hMPV by reducing viral replication and inflammation through antiviral treatments and supportive care. This improves health outcomes, especially for vulnerable groups such as infants, the elderly, and immunocompromised patients. For example, in June 2024, the Australian Institute of Health and Welfare, a government agency, reported that Chronic Obstructive Pulmonary Disease (COPD) contributed to 3.6% of Australia's total disease burden in 2023. COPD accounted for 50% of the overall respiratory disease burden, with an estimated 638,000 people (2.5% of the population) living with COPD in 2022. Therefore, the increasing prevalence of respiratory infections is driving growth in the human metapneumovirus (hMPV) therapeutics market.

Leading companies in the human metapneumovirus (hMPV) therapeutics market are focusing on developing targeted antiviral therapies, such as monoclonal antibodies, to effectively treat hMPV infections. Monoclonal antibodies (mAbs) are laboratory-produced proteins that replicate the immune system's natural ability to fight diseases. These antibodies offer targeted therapy for a range of conditions, including cancer and autoimmune disorders, by specifically binding to and neutralizing harmful antigens or cells. For instance, in October 2024, Vicebio Ltd., a UK-based biopharmaceutical company, secured $100 million in Series B financing, led by TCGX with support from Goldman Sachs Alternatives and other investors. This funding will advance the Phase 1 clinical trial of VXB-241, a bivalent vaccine targeting RSV and hMPV, with preliminary results expected by mid-2025. The funding will also accelerate the development of VXB-251, a trivalent vaccine targeting RSV, hMPV, and Parainfluenza Virus 3, aiming to address significant medical challenges in older populations.

In February 2024, AstraZeneca plc, a UK-based pharmaceutical giant, acquired Icosavax, Inc. for $1.1 billion. This acquisition allows AstraZeneca to strengthen its vaccine and respiratory infection portfolio by incorporating Icosavax's innovative virus-like particle (VLP) technology and its potential first-in-class combination vaccine for RSV and hMPV. Icosavax, Inc., a U.S.-based biopharmaceutical company, is developing virus-like particle vaccines, including a promising first-in-class combination vaccine targeting both RSV and hMPV.

Major players in the human metapneumovirus (hmpv) therapeutics market are Sanofi S.A, AstraZeneca Plc, Merck KGaA, Moderna Inc, Riverside Health System, Narayana Health, Vir Biotechnology Inc., Fortis Healthcare, Apollo Diagnostics, Pathkind Diagnostics Pvt Ltd, Max Healthcare, LalPathLabs, Bio Farma, Metropolis Healthcare, American Lung Association, Enanta Pharmaceuticals Inc., Regency Healthcare, The Native Antigen Company, Max Lab, Agilus Diagnostics.

North America was the largest region in the human metapneumovirus (hMPV) therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in human metapneumovirus (hMPV) therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the human metapneumovirus (hMPV) therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The human metapneumovirus (hMPV) therapeutics market consists of revenues earned by entities providing services such as antiviral drug development, vaccine research, diagnostic testing, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The human metapneumovirus (hMPV) therapeutics market also includes sales of antiviral medications, immunotherapies, vaccines, and related diagnostic kits. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Human Metapneumovirus (hMPV) Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on human metapneumovirus (hmpv) therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for human metapneumovirus (hmpv) therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The human metapneumovirus (hmpv) therapeutics market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Drug Class: Antipyretic; Decongestants; Cough Suppressants; Other Drug Class
• 2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
• 3) By End-Use: Hospitals And Clinics; Diagnostic And Reference Laboratories; Academic And Research Institutions; Other End-Uses
• Subsegments:
• 1) By Antipyretic: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Acetaminophen (Paracetamol)
• 2) By Decongestants: Nasal Decongestants, Oral Decongestants
• 3) By Cough Suppressants: Dextromethorphan, Codeine, Benzonatate
• 4) By Other Drug Class: Antiviral Agents, Antibiotics (if secondary bacterial infection occurs), Inhaled Corticosteroids
• Companies Mentioned: Sanofi S.A; AstraZeneca Plc; Merck KGaA; Moderna Inc; Riverside Health System
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Human Metapneumovirus (hMPV) Therapeutics Market Characteristics

3. Human Metapneumovirus (hMPV) Therapeutics Market Trends And Strategies

4. Human Metapneumovirus (hMPV) Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Human Metapneumovirus (hMPV) Therapeutics Growth Analysis And Strategic Analysis Framework

• 5.1. Global Human Metapneumovirus (hMPV) Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Human Metapneumovirus (hMPV) Therapeutics Market Growth Rate Analysis
• 5.4. Global Human Metapneumovirus (hMPV) Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Human Metapneumovirus (hMPV) Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Human Metapneumovirus (hMPV) Therapeutics Total Addressable Market (TAM)

6. Human Metapneumovirus (hMPV) Therapeutics Market Segmentation

• 6.1. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antipyretic
• Decongestants
• Cough Suppressants
• Other Drug Class
• 6.2. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals And Clinics
• Diagnostic And Reference Laboratories
• Academic And Research Institutions
• Other End-Uses
• 6.4. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Antipyretic, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• Acetaminophen (Paracetamol)
• 6.5. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Decongestants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nasal Decongestants
• Oral Decongestants
• 6.6. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Cough Suppressants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Dextromethorphan
• Codeine
• Benzonatate
• 6.7. Global Human Metapneumovirus (hMPV) Therapeutics Market, Sub-Segmentation Of Other Drug Class, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Antiviral Agents
• Antibiotics
• Inhaled Corticosteroids

7. Human Metapneumovirus (hMPV) Therapeutics Market Regional And Country Analysis

• 7.1. Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Human Metapneumovirus (hMPV) Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market

• 8.1. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Human Metapneumovirus (hMPV) Therapeutics Market

• 9.1. China Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 9.2. China Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Human Metapneumovirus (hMPV) Therapeutics Market

• 10.1. India Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Human Metapneumovirus (hMPV) Therapeutics Market

• 11.1. Japan Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 11.2. Japan Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Human Metapneumovirus (hMPV) Therapeutics Market

• 12.1. Australia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market

• 13.1. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Human Metapneumovirus (hMPV) Therapeutics Market

• 14.1. South Korea Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 14.2. South Korea Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market

• 15.1. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 15.2. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Human Metapneumovirus (hMPV) Therapeutics Market

• 16.1. UK Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Human Metapneumovirus (hMPV) Therapeutics Market

• 17.1. Germany Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Human Metapneumovirus (hMPV) Therapeutics Market

• 18.1. France Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Human Metapneumovirus (hMPV) Therapeutics Market

• 19.1. Italy Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Human Metapneumovirus (hMPV) Therapeutics Market

• 20.1. Spain Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market

• 21.1. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 21.2. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Human Metapneumovirus (hMPV) Therapeutics Market

• 22.1. Russia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Human Metapneumovirus (hMPV) Therapeutics Market

• 23.1. North America Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 23.2. North America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Human Metapneumovirus (hMPV) Therapeutics Market

• 24.1. USA Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 24.2. USA Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Human Metapneumovirus (hMPV) Therapeutics Market

• 25.1. Canada Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 25.2. Canada Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Human Metapneumovirus (hMPV) Therapeutics Market

• 26.1. South America Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 26.2. South America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Human Metapneumovirus (hMPV) Therapeutics Market

• 27.1. Brazil Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Human Metapneumovirus (hMPV) Therapeutics Market

• 28.1. Middle East Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 28.2. Middle East Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Human Metapneumovirus (hMPV) Therapeutics Market

• 29.1. Africa Human Metapneumovirus (hMPV) Therapeutics Market Overview
• 29.2. Africa Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Human Metapneumovirus (hMPV) Therapeutics Market, Segmentation By End-Use, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Human Metapneumovirus (hMPV) Therapeutics Market Competitive Landscape And Company Profiles

• 30.1. Human Metapneumovirus (hMPV) Therapeutics Market Competitive Landscape
• 30.2. Human Metapneumovirus (hMPV) Therapeutics Market Company Profiles
  • 30.2.1. Sanofi S.A Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck KGaA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Moderna Inc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Riverside Health System Overview, Products and Services, Strategy and Financial Analysis

31. Human Metapneumovirus (hMPV) Therapeutics Market Other Major And Innovative Companies

• 31.1. Narayana Health
• 31.2. Vir Biotechnology Inc.
• 31.3. Fortis Healthcare
• 31.4. Apollo Diagnostics
• 31.5. Pathkind Diagnostics Pvt Ltd
• 31.6. Max Healthcare
• 31.7. LalPathLabs
• 31.8. Bio Farma
• 31.9. Metropolis Healthcare
• 31.10. American Lung Association
• 31.11. Enanta Pharmaceuticals Inc.
• 31.12. Regency Healthcare
• 31.13. The Native Antigen Company
• 31.14. Max Lab
• 31.15. Agilus Diagnostics

32. Global Human Metapneumovirus (hMPV) Therapeutics Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Human Metapneumovirus (hMPV) Therapeutics Market

34. Recent Developments In The Human Metapneumovirus (hMPV) Therapeutics Market

35. Human Metapneumovirus (hMPV) Therapeutics Market High Potential Countries, Segments and Strategies

• 35.1 Human Metapneumovirus (hMPV) Therapeutics Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Human Metapneumovirus (hMPV) Therapeutics Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Human Metapneumovirus (hMPV) Therapeutics Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer
• 250617_r34872_Human_Metapneumovirus_hMPV_Therapeutics_GMR_2025